JP2018527355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527355A5 JP2018527355A5 JP2018511626A JP2018511626A JP2018527355A5 JP 2018527355 A5 JP2018527355 A5 JP 2018527355A5 JP 2018511626 A JP2018511626 A JP 2018511626A JP 2018511626 A JP2018511626 A JP 2018511626A JP 2018527355 A5 JP2018527355 A5 JP 2018527355A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- formula
- alkyl
- acyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 78
- 125000003118 aryl group Chemical group 0.000 claims description 60
- 125000002252 acyl group Chemical group 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- -1 each of which Chemical group 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 125000004185 ester group Chemical group 0.000 claims description 30
- 125000002837 carbocyclic group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 19
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005002 aryl methyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000012385 systemic delivery Methods 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 238000012384 transportation and delivery Methods 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 5
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 5
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 5
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 5
- 229960002646 scopolamine Drugs 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 description 19
- 0 CC(C)(C)OC(N(C(CC(C1)C2)C3*)C1C3N2C(c(cc1)ncc1F)=O)=O Chemical compound CC(C)(C)OC(N(C(CC(C1)C2)C3*)C1C3N2C(c(cc1)ncc1F)=O)=O 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214734P | 2015-09-04 | 2015-09-04 | |
| US201562214727P | 2015-09-04 | 2015-09-04 | |
| US62/214,727 | 2015-09-04 | ||
| US62/214,734 | 2015-09-04 | ||
| PCT/US2016/049893 WO2017040778A1 (en) | 2015-09-04 | 2016-09-01 | Therapeutic compound for pain and synthesis thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527355A JP2018527355A (ja) | 2018-09-20 |
| JP2018527355A5 true JP2018527355A5 (enExample) | 2018-11-22 |
| JP6868008B2 JP6868008B2 (ja) | 2021-05-12 |
Family
ID=58188341
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511626A Expired - Fee Related JP6868008B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
| JP2018511607A Expired - Fee Related JP6736661B2 (ja) | 2015-09-04 | 2016-09-01 | 治療化合物及び合成 |
| JP2018511601A Expired - Fee Related JP6736659B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
| JP2018511605A Expired - Fee Related JP6736660B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
| JP2018511670A Expired - Fee Related JP6639651B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511607A Expired - Fee Related JP6736661B2 (ja) | 2015-09-04 | 2016-09-01 | 治療化合物及び合成 |
| JP2018511601A Expired - Fee Related JP6736659B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
| JP2018511605A Expired - Fee Related JP6736660B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
| JP2018511670A Expired - Fee Related JP6639651B2 (ja) | 2015-09-04 | 2016-09-01 | 疼痛のための治療化合物及びその合成 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US9994572B2 (enExample) |
| EP (5) | EP3344626B9 (enExample) |
| JP (5) | JP6868008B2 (enExample) |
| CN (5) | CN109153679B (enExample) |
| CA (5) | CA2997541C (enExample) |
| DK (4) | DK3344614T5 (enExample) |
| ES (4) | ES2812233T3 (enExample) |
| IL (5) | IL257732B (enExample) |
| MA (1) | MA45011A (enExample) |
| TW (11) | TWI713879B (enExample) |
| WO (5) | WO2017040767A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6868008B2 (ja) * | 2015-09-04 | 2021-05-12 | ヤンセン ファーマシューティカ エヌ．ベー． | 疼痛のための治療化合物及びその合成 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1469781A (en) * | 1974-06-10 | 1977-04-06 | Boehringer Sohn Ingelheim | Production of scopine |
| US4232026A (en) * | 1978-07-20 | 1980-11-04 | Merck & Co., Inc. | Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4532244A (en) * | 1984-09-06 | 1985-07-30 | Innes Margaret N | Method of treating migraine headaches |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5422354A (en) * | 1990-07-23 | 1995-06-06 | Pfizer Inc | Quinuclidine derivatives |
| DE553264T1 (de) | 1990-10-05 | 1994-04-28 | Wayne M Barnes | Thermostabile dna polymerase. |
| US6432976B1 (en) * | 1999-10-29 | 2002-08-13 | Merck & Co., Inc. | 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
| DE10050994A1 (de) * | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| ATE435862T1 (de) * | 2003-05-28 | 2009-07-15 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
| CA2539811A1 (en) * | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| WO2007024814A1 (en) * | 2005-08-22 | 2007-03-01 | Targacept, Inc. | HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF |
| US8735411B2 (en) * | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| WO2008104955A1 (en) * | 2007-02-28 | 2008-09-04 | Ranbaxy Laboratories Limited | Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists |
| TW200840569A (en) | 2007-03-13 | 2008-10-16 | Targacept Inc | Sub-type selective amides of diazabicycloalkanes |
| WO2009124755A1 (en) * | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
| CN101768158B (zh) * | 2010-01-04 | 2013-05-29 | 南昌弘益科技有限公司 | 噻托溴铵无水物及其制备方法 |
| CN102579458A (zh) * | 2012-03-08 | 2012-07-18 | 冀中能源峰峰集团有限公司总医院 | 缓解静点药物所致疼痛和防治静脉炎的药品配方 |
| JP6102122B2 (ja) * | 2012-08-24 | 2017-03-29 | ソニー株式会社 | 画像処理装置および方法、並びにプログラム |
| BR112015006029B1 (pt) * | 2012-09-18 | 2022-01-25 | Heptares Therapeutics Limited | Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias |
| TW201444849A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TWI627174B (zh) * | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| KR20160115503A (ko) * | 2015-03-27 | 2016-10-06 | 차의과학대학교 산학협력단 | 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법 |
| GB201505654D0 (en) * | 2015-04-01 | 2015-05-13 | Nordic Bioscience As | Immunoassay for collagen type VI sequence |
| GB201505701D0 (en) * | 2015-04-02 | 2015-05-20 | Byotrol Plc | Anti-microbial composition |
| JP6868008B2 (ja) * | 2015-09-04 | 2021-05-12 | ヤンセン ファーマシューティカ エヌ．ベー． | 疼痛のための治療化合物及びその合成 |
-
2016
- 2016-09-01 JP JP2018511626A patent/JP6868008B2/ja not_active Expired - Fee Related
- 2016-09-01 CA CA2997541A patent/CA2997541C/en active Active
- 2016-09-01 CN CN201680064788.XA patent/CN109153679B/zh not_active Expired - Fee Related
- 2016-09-01 WO PCT/US2016/049877 patent/WO2017040767A1/en not_active Ceased
- 2016-09-01 DK DK16842971.0T patent/DK3344614T5/da active
- 2016-09-01 DK DK16842975.1T patent/DK3344627T5/da active
- 2016-09-01 WO PCT/US2016/049871 patent/WO2017040764A1/en not_active Ceased
- 2016-09-01 US US15/254,944 patent/US9994572B2/en active Active
- 2016-09-01 WO PCT/US2016/049893 patent/WO2017040778A1/en not_active Ceased
- 2016-09-01 CA CA2997545A patent/CA2997545C/en active Active
- 2016-09-01 ES ES16842976T patent/ES2812233T3/es active Active
- 2016-09-01 EP EP16842973.6A patent/EP3344626B9/en active Active
- 2016-09-01 JP JP2018511607A patent/JP6736661B2/ja not_active Expired - Fee Related
- 2016-09-01 CA CA2997543A patent/CA2997543C/en active Active
- 2016-09-01 CN CN201680064801.1A patent/CN108495854B/zh not_active Expired - Fee Related
- 2016-09-01 US US15/254,938 patent/US10040795B2/en active Active
- 2016-09-01 EP EP16842975.1A patent/EP3344627B9/en active Active
- 2016-09-01 EP EP16842976.9A patent/EP3344628B9/en active Active
- 2016-09-01 US US15/254,960 patent/US10040797B2/en active Active
- 2016-09-01 MA MA045011A patent/MA45011A/fr unknown
- 2016-09-01 CN CN201680064673.0A patent/CN108290890B/zh not_active Expired - Fee Related
- 2016-09-01 CA CA2997430A patent/CA2997430C/en active Active
- 2016-09-01 US US15/254,965 patent/US10155762B2/en active Active
- 2016-09-01 DK DK16842976.9T patent/DK3344628T5/da active
- 2016-09-01 EP EP16842971.0A patent/EP3344614B9/en active Active
- 2016-09-01 DK DK16842973.6T patent/DK3344626T5/da active
- 2016-09-01 ES ES16842973T patent/ES2807901T3/es active Active
- 2016-09-01 ES ES16842971T patent/ES2809703T3/es active Active
- 2016-09-01 CN CN201680064790.7A patent/CN108349934B/zh not_active Expired - Fee Related
- 2016-09-01 CA CA2997501A patent/CA2997501C/en active Active
- 2016-09-01 WO PCT/US2016/049881 patent/WO2017040770A1/en not_active Ceased
- 2016-09-01 JP JP2018511601A patent/JP6736659B2/ja not_active Expired - Fee Related
- 2016-09-01 CN CN201680064789.4A patent/CN109071540B/zh not_active Expired - Fee Related
- 2016-09-01 US US15/254,952 patent/US10040796B2/en active Active
- 2016-09-01 ES ES16842975T patent/ES2808048T3/es active Active
- 2016-09-01 EP EP16842981.9A patent/EP3344629A4/en not_active Withdrawn
- 2016-09-01 JP JP2018511605A patent/JP6736660B2/ja not_active Expired - Fee Related
- 2016-09-01 WO PCT/US2016/049885 patent/WO2017040772A1/en not_active Ceased
- 2016-09-01 JP JP2018511670A patent/JP6639651B2/ja not_active Expired - Fee Related
- 2016-09-02 TW TW107128718A patent/TWI713879B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107101163A patent/TWI672303B/zh not_active IP Right Cessation
- 2016-09-02 TW TW106142501A patent/TWI695836B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128530A patent/TWI636054B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128528A patent/TWI654188B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107117875A patent/TWI686393B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128533A patent/TWI641608B/zh not_active IP Right Cessation
- 2016-09-02 TW TW108103711A patent/TWI683815B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128529A patent/TWI639597B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128531A patent/TWI663167B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107120678A patent/TWI707854B/zh not_active IP Right Cessation
-
2018
- 2018-02-26 IL IL257732A patent/IL257732B/en active IP Right Grant
- 2018-02-26 IL IL257740A patent/IL257740A/en active IP Right Grant
- 2018-02-26 IL IL257734A patent/IL257734B/en unknown
- 2018-02-26 IL IL257737A patent/IL257737B2/en unknown
- 2018-02-26 IL IL257735A patent/IL257735B/en unknown
- 2018-06-11 US US16/005,366 patent/US10351565B2/en active Active
- 2018-07-24 US US16/043,829 patent/US10358448B2/en active Active
- 2018-07-24 US US16/043,813 patent/US10351566B2/en active Active
- 2018-12-17 US US16/222,852 patent/US10766898B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500870A5 (enExample) | ||
| JP7064772B2 (ja) | 選択的エストロゲン受容体ダウンレギュレーター（ｓｅｒｄｓ） | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| WO2020227549A8 (en) | MODULATORS OF THR-β AND METHODS OF USE THEREOF | |
| JP2016527277A5 (enExample) | ||
| RU2010145529A (ru) | Композиции гидрофобных производных таксана и их применение | |
| JP2019524883A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| CA2551409A1 (en) | Prostaglandin nitrooxyderivatives | |
| JP2015537020A5 (enExample) | ||
| JP2019521988A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2008545793A5 (enExample) | ||
| JP2009519243A5 (enExample) | ||
| JP2009536221A5 (enExample) | ||
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| CN106928081B (zh) | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
| JP2010517955A5 (enExample) | ||
| JP2013519653A5 (enExample) | ||
| JP2015512413A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2017522304A5 (enExample) |